Annexon, Inc. (NASDAQ:ANNX) Shares Sold by TD Asset Management Inc

TD Asset Management Inc reduced its holdings in Annexon, Inc. (NASDAQ:ANNX) by 64.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 46,848 shares of the company’s stock after selling 86,800 shares during the period. TD Asset Management Inc’s holdings in Annexon were worth $90,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Point72 Asset Management L.P. lifted its stake in Annexon by 5.6% in the 4th quarter. Point72 Asset Management L.P. now owns 5,626,796 shares of the company’s stock valued at $28,865,000 after buying an additional 299,798 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Annexon by 11.6% during the fourth quarter. Vanguard Group Inc. now owns 5,546,918 shares of the company’s stock valued at $28,456,000 after acquiring an additional 576,625 shares during the last quarter. Nuveen Asset Management LLC lifted its position in shares of Annexon by 6.5% in the fourth quarter. Nuveen Asset Management LLC now owns 2,720,485 shares of the company’s stock valued at $13,956,000 after acquiring an additional 164,915 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Annexon by 1.3% in the fourth quarter. Geode Capital Management LLC now owns 2,171,478 shares of the company’s stock valued at $11,142,000 after acquiring an additional 27,843 shares in the last quarter. Finally, TFG Asset Management GP Ltd boosted its stake in shares of Annexon by 78.5% in the fourth quarter. TFG Asset Management GP Ltd now owns 1,400,000 shares of the company’s stock worth $7,182,000 after acquiring an additional 615,645 shares during the last quarter.

Annexon Stock Performance

NASDAQ:ANNX opened at $2.48 on Wednesday. The stock has a 50 day moving average price of $2.48 and a 200 day moving average price of $2.46. The stock has a market cap of $272.08 million, a PE ratio of -2.10 and a beta of 1.30. Annexon, Inc. has a one year low of $1.28 and a one year high of $7.85.

Annexon (NASDAQ:ANNX) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.07). As a group, analysts predict that Annexon, Inc. will post -0.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Needham & Company LLC decreased their price objective on Annexon from $16.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, May 13th. HC Wainwright reduced their target price on shares of Annexon from $20.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, May 14th.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.